First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: An open-label, randomized, multicentre clinical trial

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2376-2381

  Cuadrado Lavín, Antonio ^a   Salcines Caviedes, J Ramón ^b   Diaz Perez, Ainhoa ^b   Carrascosa, Miguel F ^c   Ochagavía, María ^a   Fernandez Forcelledo, José Luis ^d   Cobo, Marta ^b   Fernández Gil, Pedro ^a   Ayestarán, Blanca ^b   Sánchez, Blanca ^a   Campo, Cristina ^e   Llorca, Javier ^f,g   Lorenzo, Silvia ^d   Illaro, Aitziber ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Hospital Comarcal de Laredo IDIVAL   (Spain)

^c Hospital of Laredo IDIVAL   (Spain)

^d Hospital Comarcal Sierrallana   (Spain)

^e Clinical Trial Agency   (Spain)

^f UNIVERSITY OF CANTABRIA   (Spain)

^g University of Cantabria IDIVAL ^*  (Spain)

Author keywords

Concomitant; H. pylori; Hybrid; Non bismuth based quadruple regimens; Randomized clinical trials

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR; UREA;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DYSPEPSIA; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METALLIC TASTE; MUCOSAL DISEASE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; UREA BREATH TEST; ADOLESCENT; BREATH ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; BREATH TESTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84939539659     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv089     Document Type: Article

References (26)

1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
2. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
3. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011; 34: 604-17.
4. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
5. Sanchez-Delgado J, Calvet X, Bujanda L et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008; 103: 2220-3.
6. Adrian G, McNicholl OPN, Gisbert JP. Sequential and concomitant treatments in H. pylori eradication: a network meta-analysis. Gastroenterology 2014; 146: S-395.
7. Gisbert JP, Calvet X, Bermejo F et al. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013; 36: 340-74.
8. Molina-Infante J, Romano M, Fernandez-Bermejo M et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-8.e1.
9. Hsu PI, Wu DC, Wu JY et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-45.
10. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008; 68: 725-36.
11. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 2012; 67: 170-3.
12. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
13. Wu JY, Hsu PI, Wu DC et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter 2014; 19: 207-13.
14. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother 2012; 67: 2254-9.
15. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-68.
16. McNicholl AG, Marin AC, Molina-Infante J et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-9.
17. Zullo A, Rinaldi V, Winn S et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-8.
18. De Francesco V, Zullo A, Hassan C et al. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Dig Liver Dis 2001; 33: 676-9.
19. Fakheri H, Taghvaei T, Hosseini V et al. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012; 17: 43-8.
20. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
21. Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-14.
22. Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20: 10338-47.
23. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86.e3; Discussion e12-3.
24. Zullo A, Scaccianoce G, De Francesco V et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647-50.
25. Federico A, Gravina AG, Miranda A et al. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol 2014; 20: 665-72.
26. Wang B, Wang YH, Lv ZF et al. Efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20: 79-88.